These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18301416)

  • 1. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.
    Nelson MR; Bacanu SA; Mosteller M; Li L; Bowman CE; Roses AD; Lai EH; Ehm MG
    Pharmacogenomics J; 2009 Feb; 9(1):23-33. PubMed ID: 18301416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions.
    Thygesen H; Su TL; Whitehead J; Bowman C
    J Biopharm Stat; 2011 Jan; 21(1):111-24. PubMed ID: 21191858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
    Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
    Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
    Hughes AR; Spreen WR; Mosteller M; Warren LL; Lai EH; Brothers CH; Cox C; Nelsen AJ; Hughes S; Thorborn DE; Stancil B; Hetherington SV; Burns DK; Roses AD
    Pharmacogenomics J; 2008 Dec; 8(6):365-74. PubMed ID: 18332899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
    Borroni RG
    G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
    Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
    Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human leukocyte antigens and drug hypersensitivity.
    Chung WH; Hung SI; Chen YT
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].
    Muñoz de Benito RM; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of drug hypersensitivity.
    Phillips EJ; Mallal SA
    Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics of adverse drug reactions: implementing personalized medicine.
    Wei CY; Lee MT; Chen YT
    Hum Mol Genet; 2012 Oct; 21(R1):R58-65. PubMed ID: 22907657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.
    Alfirevic A; Pirmohamed M
    Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
    Nolan D
    Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
    Nolan D; Gaudieri S; Mallal S
    J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Phillips EJ
    Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.